|
Nektar (R) Therapeutics, founded in 1990 and based in San Carlos, California, is a biopharmaceutical company that develops diabetes and anti-infection drugs and delivery technologies. The firm's PEGylation technology improves the efficacy and safety of existing medicines. Nektar Therapeutics has formed partnerships with Pfizer, Amgen, UCB Pharma, Bristol-Myers-Squibb, Confluent Surgical, Roche, OSE-Eyetech, and Schering-Plough. The company is known for the Exubera (R) insulin inhalation powder, sold by Pfizer, which treats Type 1 and 2 diabetes. The firm also develops the Neulasta (R) neutropenia, Cimzia Crohn's disease, DEFINITY (R) Vial cardiac imaging, DuraSeal (R) cranial dural sealant, and Macugen (R) age-related macular degeneration, and the PEGASYS (R) and PEG-INTRON (R) hepatitis C products. The company's pulmonary delivery products encompass dry powder and liquid drug delivery technologies. The firm was founded as Inhale Therapeutic Systems Incorporated. It was renamed in 2003. In the same year, the company acquired drug development companies Shearwater and Aerogen. Nektar Therapeutics maintains additional offices in the United States, India, and Ireland. The firm is listed on NASDAQ under the NKTR symbol. Nektar Therapeutics is developing new cancer, pain, and infection treatments.
|
Information Sources, Inc.